Navigating New Evidence in the Treatment of HER2-Expressing Metastatic Breast Cancer in Rural and Underserved Communities

Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.

Program Overview
Over the past decades, the emergence of novel targeted therapies in combination with endocrine therapy has improved outcomes for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. However, oncology clinicians in rural and underserved areas are challenged to stay abreast of emerging evidence and face multiple barriers such as clinician shortages, long travel distances, and limited access to the latest treatments. In this activity, expert faculty will review the latest clinical data for treatment of HR-positive, HER2-negative breast cancer in the early and metastatic settings. Multidisciplinary strategies to reduce health disparities and address inequities in breast cancer across the care continuum will also be discussed.

This enduring activity is a recorded session from Oncology Congress that took place on April 1, 2023.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Explain the evolving role of HER2 testing in determining treatment selection in patients with HER2-expressing breast cancer
Evaluate the efficacy and safety of current and emerging treatments for HER2-expressing metastatic breast cancer
Integrate current guidelines and clinical evidence on sequencing of therapies into personalized treatment plans for patients with HER2-expressing metastatic breast cancer
Identify evidence-based strategies for reducing disparities in breast cancer care access and treatment in rural and underserved settings